Norihiro Fujinami, Yu Sawada, Daisuke Nobuoka and Tetsuya Nakatsura
The clinical efficacy of cancer peptide vaccines has been considered inadequate. To enhance the anti-tumor effects of peptide vaccines, we have studied effective enhancement methods for peptide vaccine therapies such as intratumoral peptide injection and combination therapies with anti-PD-1 blocking antibody or anti-CD4 depletion antibody. We aim to present effective clinical applications of peptide vaccines.